Zimmer Biomet Holdings, Inc.

Zimmer Biomet maintains a leveraged capital structure with total debt of $7.47 billion against $12.67 billion in equity, resulting in a debt-to-equity ratio of 0.59. The company holds $424.2 million in cash and equivalents, leading to a negative net cash position. Liquidity is assessed as medium, supported by a current ratio of 1.73, which indicates adequate short-term asset coverage for liabilities.

Profitability metrics show a return on equity of 5.56% and a return on assets of 3.1% for the latest period. The company trades at a price-to-earnings ratio of 22.03 and an EV/EBITDA of 10.30. Without cohort median data provided, these returns are evaluated in isolation, noting that the operating income of $373.2 million on $2.09 billion in revenue yields a healthy operating margin.

Revenue concentration by segment and geography is not detailed in the available data. The analysis relies on aggregate financial figures, omitting specific breakdowns of product lines or regional exposure due to the absence of segment and geography tables.

Growth trajectory analysis is limited by the absence of historical period data. The current revenue of $2.09 billion for Q1 2026 serves as the baseline, but year-over-year or multi-year trends cannot be computed from the provided input.

Risk assessment highlights medium liquidity risk and unknown dilution risk. Key flags indicate that net cash is negative after subtracting total debt, and dilution risk could not be assessed due to missing basic and diluted share count distinctions. The company faces standard operational risks including competition, pricing pressures, and regulatory changes.

Recent observations include analyst price targets with a mean of $98.96 and a median of $95.00, suggesting upside potential from the current market price of $79.33. The mean recommendation is 2.72, indicating a neutral-to-buy consensus. Filing observations note forward-looking statements regarding sales guidance and risks related to restructuring, acquisitions, and supply chain disruptions.

Zimmer Biomet Holdings, Inc. (ZBH) experienced a major shift in institutional ownership as investor ID 587 significantly adjusted its position in the company’s stock. The investor initially reduced its holdings from 140,266 shares, valued at approximately $12.68 million, to just 5,371 shares, worth roughly $0.49 million, as of March 31, 2026. This substantial decrease represented a drop in portfolio weight from 0.0073% to 0.00028%. However, the investor subsequently reversed this course, increasing its stake back to 140,266 shares, restoring the position’s value to $12.68 million and its weight to 0.0073% of the portfolio. This rapid reversal occurred within a two-day window, with the initial reduction detected on June 23, 2026, and the reinstatement detected on June 21, 2026, indicating a volatile or corrected reporting period for this specific holder. These movements highlight the dynamic nature of ZBH’s shareholder base, which currently includes 35 top holders. The company maintains a lean executive structure with only one officer on record and is included in one major index, suggesting a focused corporate governance model despite the fluctuations in specific institutional positions. As this is the first analysis for ZBH, there is no prior basis for computing delta changes in broader metrics. The absence of analyst coverage, indicated by an analyst count of zero, means that market sentiment and valuation benchmarks are currently driven by holder activity and index inclusion rather than consensus estimates or widespread professional scrutiny.

Cash conversion ratio of 2.41 is best-in-class compared to the cohort median of 0.98, demonstrating strong cash generation.

Free cash flow fell 12.0% year-over-year in FY2025, raising concerns about the sustainability of cash generation capabilities.

Long-term debt increased to $6.9 billion in FY2025, reflecting a rising leverage profile that may constrain financial flexibility.

Revenue growth slowed to a 1.9% CAGR from FY2023 to FY2025, indicating weak top-line momentum in the market.

The company faces medium liquidity and credit risk flags, suggesting potential vulnerabilities in its financial stability.

Revenue $2.09B; Operating income $373.2M.

• ▍Revenue $2.09B
• ▍Operating income $373.2M
• ▍Net margin 11.4%

Revenue $5.99B; Operating income $943.6M.

• ▍Revenue $5.99B
• ▍Operating income $943.6M
• ▍Net margin 9.4%

Revenue $3.99B; Operating income $592.3M.

• ▍Revenue $3.99B
• ▍Operating income $592.3M
• ▍Net margin 8.4%

Revenue $8.23B; Operating income $1.10B.

• ▍Revenue $8.23B
• ▍Operating income $1.10B
• ▍Net margin 8.6%

Revenue $7.68B; Operating income $1.29B.

• ▍Revenue $7.68B
• ▍Operating income $1.29B
• ▍Net margin 11.8%

Revenue $7.68B; Operating income $1.29B.

• ▍Revenue $7.68B
• ▍Operating income $1.29B
• ▍Net margin 11.8%

Revenue $7.39B; Operating income $1.28B.

• ▍Revenue $7.39B
• ▍Operating income $1.28B
• ▍Net margin 13.8%

Revenue $7.39B; Operating income $1.28B.

• ▍Revenue $7.39B
• ▍Operating income $1.28B
• ▍Net margin 13.8%